| Date | Title | Description |
| 20.09.2024 | Navigating the Warrant Landscape: A Look at Brain+ and Diagonal Bio | In the world of finance, warrants are like keys to a treasure chest. They offer investors the chance to unlock new shares at a predetermined price. Recently, two companies, Brain+ A/S and Diagonal Bio AB, have made headlines with their warr... |
| 20.09.2024 | Brain+ A/S announces additional commitments of DKK 1.4 million in the ongoing TO 4 warrant exercise, which is now covered at 40.4% | Brain+ A/S announces additional commitments of DKK 1.4 million in the ongoing TO 4 warrant exercise, which is now covered at 40.4%
Fri, Sep 20, 2024 08:43 CET Report this content
Copenhagen, Denmark, 20 September 2024 – Brain+ A/S (Nasdaq F... |
| 19.09.2024 | The last day of trading in warrants of series TO 1 is on the 24th of September 2024 | The last day of trading in warrants of series TO 1 is on the 24th of September 2024
Thu, Sep 19, 2024 08:30 CET Report this content Read original
The 24th of September 2024 is the last day of trading in warrants of series TO 1, which were i... |
| 17.09.2024 | Brain+ A/S announces that its board and management provide commitments to cover 13.7% of the warrants of series TO 4 | Brain+ A/S announces that its board and management provide commitments to cover 13.7% of the warrants of series TO 4
Tue, Sep 17, 2024 10:46 CET Report this content
Copenhagen, Denmark, 17 September 2024 – Brain+ A/S (Nasdaq First North: BR... |
| 14.09.2024 | Curasight and Brain+: Navigating the Waters of Rights Issues and Warrants | In the bustling world of biotech, companies often seek new avenues for funding. Two Danish firms, Curasight A/S and Brain+ A/S, recently made headlines with their respective rights issues and warrant exercises. These financial maneuvers are... |
| 13.09.2024 | Brain+ A/S announces the exercise price for its warrants of series TO 4 | Brain+ A/S announces the exercise price for its warrants of series TO 4
Fri, Sep 13, 2024 09:08 CET Report this content
Copenhagen, Denmark, 13 September 2024 – Brain+ A/S (Nasdaq First North: BRAINP)
The exercise price of the warrants of s... |
| 12.09.2024 | Curasight A/S publishes prospectus due to upcoming rights issue | Curasight A/S publishes prospectus due to upcoming rights issue
Thu, Sep 12, 2024 12:22 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, C... |
| 12.09.2024 | The exercise period for warrants of series TO 4 commences today | The exercise period for warrants of series TO 4 commences today
Thu, Sep 12, 2024 08:55 CET Report this content
Today is the first day for the exercise of Phase Holographic Imaging PHI AB's ("PHI" or "Company") warrants ... |
| 12.09.2024 | The exercise period for warrants of series TO 1 commences today | The exercise period for warrants of series TO 1 commences today
Thu, Sep 12, 2024 08:30 CET Report this content Read original
Today is the first day for the exercise of Diagonal Bio AB's ("Diagonal Bio" or "the Company")... |
| 11.09.2024 | Navigating the Warrant Landscape: A Look at Diagonal Bio and PHI | In the world of biotechnology, warrants can be a double-edged sword. They offer potential, but they also come with risks. Recently, two companies, Diagonal Bio AB and Phase Holographic Imaging (PHI) AB, announced the exercise prices for the... |
| 11.09.2024 | The exercise price for warrants of series TO 1 has been set to SEK 0,05 per new share | The exercise price for warrants of series TO 1 has been set to SEK 0,05 per new share
Wed, Sep 11, 2024 09:00 CET Report this content Read original
Diagonal Bio AB ("Diagonal Bio" or "the Company") hereby announces that ... |
| 11.09.2024 | The exercise price for warrants of series TO 4 has been set to SEK 4.63 per new share | The exercise price for warrants of series TO 4 has been set to SEK 4.63 per new share
Wed, Sep 11, 2024 09:36 CET Report this content
Phase Holographic Imaging PHI AB ("PHI" or "the Company") hereby announces that the ex... |
| 05.09.2024 | DexTech and Curasight: Navigating the Waters of Medical Innovation and Financing | In the ever-evolving landscape of medical technology, two companies stand out: DexTech Medical AB and Curasight A/S. Both are charting their courses through clinical trials and financial maneuvers, aiming to bring innovative treatments to m... |
| 04.09.2024 | The Board of Directors resolves on a directed issue of units and preferential rights issue of units | The Board of Directors resolves on a directed issue of units and preferential rights issue of units
Wed, Sep 04, 2024 09:25 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED ST... |
| 26.08.2024 | Cyxone AB announces last day of trading in BTA | Cyxone AB announces last day of trading in BTA
Mon, Aug 26, 2024 14:19 CET Report this content
Cyxone AB’s ("Cyxone" or the "Company") rights issue, with a subscription period ending on 15 August 2024, has now been regis... |
| 16.08.2024 | Cyxone AB publishes outcome of rights issue | Cyxone AB publishes outcome of rights issue
Fri, Aug 16, 2024 08:59 CET Report this content
The subscription period in Cyxone AB’s ("Cyxone" or the "Company") rights issue ended on 15 August 2024 (the "Rights Issue&... |
| 03.08.2024 | Cyxone's Rights Issue: A Crucial Step Towards Innovation in Autoimmune Treatments | Cyxone AB, a Swedish biopharmaceutical company, is making waves in the healthcare sector. Today marks the beginning of a pivotal moment for the company: the subscription period for its rights issue. This initiative aims to raise up to SEK 2... |
| 01.08.2024 | The subscription period in Cyxone’s rights issue starts today | The subscription period in Cyxone’s rights issue starts today
Thu, Aug 01, 2024 08:45 CET Report this content
Today, 1 August 2024, the subscription period in Cyxone AB’s ("Cyxone" or "the Company") issue of shares (the ... |
| 31.07.2024 | Cyxone AB publishes investment memorandum | Cyxone AB publishes investment memorandum
Wed, Jul 31, 2024 08:45 CET Report this content
On 23 July 2024, the board of Cyxone AB (publ) ("Cyxone" or the "Company"), resolved to carry out a preferential rights issue of s... |
| 23.07.2024 | The board decides on a rights issue of a maximum of approximately SEK 23 million to finance continued development of rabeximod and T20K | The board decides on a rights issue of a maximum of approximately SEK 23 million to finance continued development of rabeximod and T20K
Tue, Jul 23, 2024 08:30 CET Report this content
The board of Cyxone AB (publ), corporate no. 559020-5471... |
| 05.07.2024 | Directed issue of units to guarantors and registration of shares from both the rights issue and the directed issue | Directed issue of units to guarantors and registration of shares from both the rights issue and the directed issue
Fri, Jul 05, 2024 13:34 CET Report this content
Copenhagen, Denmark, 5 July 2024 – Brain+ A/S (Nasdaq First North: BRAINP)
Th... |
| 28.06.2024 | Carbiotix AB’s warrant exercise registered at the Swedish Companies Registration Office | Carbiotix AB’s warrant exercise registered at the Swedish Companies Registration Office
Fri, Jun 28, 2024 08:45 CET Report this content
Carbiotix AB ("Carbiotix" or "Company") today announces that the new shares from the... |
| 27.06.2024 | Brain+ A/S publishes the outcome of its rights issue of units | Brain+ A/S publishes the outcome of its rights issue of units
Thu, Jun 27, 2024 10:08 CET Report this content
Copenhagen, Denmark, June 27 2024 – Brain+ A/S (Nasdaq First North: BRAINP)
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY... |
| 24.06.2024 | Brain+ obtains additional guarantee commitment in its ongoing rights issue | Brain+ obtains additional guarantee commitment in its ongoing rights issue
Mon, Jun 24, 2024 10:06 CET Report this content
Copenhagen, Denmark, 24 June 2024 – Brain+ A/S (Nasdaq First North: BRAINP)
Brain+ A/S (“Brain+” or the “Company”) an... |
| 21.06.2024 | Last day for subscription in the ongoing rights issue | Last day for subscription in the ongoing rights issue
Fri, Jun 21, 2024 08:45 CET Report this content
Copenhagen, Denmark, 21 June, 2024 – Brain+ A/S (Nasdaq First North: BRAINP)
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR IND... |
| 20.06.2024 | Carbiotix AB announces the outcome of the exercise of warrants of series TO 3 | Carbiotix AB announces the outcome of the exercise of warrants of series TO 3
Thu, Jun 20, 2024 20:00 CET Report this content
On June 19, 2024, the exercise period for Carbiotix AB's ("Carbiotix" or "Company") warrants o... |
| 20.06.2024 | Brain+ receives guarantee commitment from health tech specialized German investment boutique and additional subscription from management in its ongoing rights issue | Brain+ receives guarantee commitment from health tech specialized German investment boutique and additional subscription from management in its ongoing rights issue
Thu, Jun 20, 2024 12:37 CET Report this content
Copenhagen, Denmark, 20 Jun... |
| 20.06.2024 | Correction - Brain+ receives guarantee commitment from health tech specialized German investment boutique and additional subscription from management in its ongoing rights issue | Correction - Brain+ receives guarantee commitment from health tech specialized German investment boutique and additional subscription from management in its ongoing rights issue
Thu, Jun 20, 2024 13:50 CET Report this content
The company an... |
| 13.06.2024 | The last day of trading in warrants of series TO 3 is on the 17th of June 2024 | The last day of trading in warrants of series TO 3 is on the 17th of June 2024
Thu, Jun 13, 2024 08:45 CET Report this content
The 17th of June 2024 is the last day of trading in warrants of series TO 3, which were issued in connection with... |
| 11.06.2024 | The subscription period in Brain+ unit rights issue begins today | The subscription period in Brain+ unit rights issue begins today
Tue, Jun 11, 2024 08:47 CET Report this content
Copenhagen, Denmark, 11 June 2024 – Brain+ A/S (Nasdaq First North: BRAINP)
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIREC... |
| 05.06.2024 | The exercise period for warrants of series TO 3 commences today | The exercise period for warrants of series TO 3 commences today
Wed, Jun 05, 2024 08:30 CET Report this content
Today is the first day for the exercise of Carbiotix AB's ("Carbiotix" or "Company") warrants of series TO 3... |
| 04.06.2024 | Brain+ A/S informs of the last day of trading in its shares including preferential rights to subscribe in the upcoming unit rights issue | Brain+ A/S informs of the last day of trading in its shares including preferential rights to subscribe in the upcoming unit rights issue
Tue, Jun 04, 2024 08:30 CET Report this content
Copenhagen, Denmark, 4 June 2024 – Brain+ A/S (Nasdaq F... |
| 03.06.2024 | The exercise price for warrants of series TO 3 has been set to SEK 0.04 per new share | The exercise price for warrants of series TO 3 has been set to SEK 0.04 per new share
Mon, Jun 03, 2024 19:00 CET Report this content
Carbiotix AB ("Carbiotix" or "the Company") hereby announces that the exercise price f... |
| 31.05.2024 | Brain+ A/S: Publication of investment brochure | Brain+ A/S: Publication of investment brochure
Fri, May 31, 2024 13:59 CET Report this content
Copenhagen, Denmark, 31 May 2024 – Brain+ A/S (Nasdaq First North: BRAINP)
The Board of Directors of Brain+ A/S (“Brain+” or the “Company”) decid... |
| 15.05.2024 | Redsense Medical presents at Sedermeradagen Stockholm 2024 | Redsense Medical presents at Sedermeradagen Stockholm 2024
Wed, May 15, 2024 15:07 CET Report this content
Sedermera Corporate Finance will once again host Sedermeradagen on May 22, 2024. The event will take place at Hotel At Six in Stockho... |
| 07.05.2024 | Brain+ A/S announce a partially secured rights issue of units of approximately DKK 8.94 million to fund operations and execution of its UK commercialization plan | Brain+ A/S announce a partially secured rights issue of units of approximately DKK 8.94 million to fund operations and execution of its UK commercialization plan
Tue, May 07, 2024 08:52 CET Report this content
Copenhagen, Denmark, 7 May 202... |
| 07.05.2024 | Diagonal Bio AB announces last day of trading in BTU and first day of trading in TO 1 | Diagonal Bio AB announces last day of trading in BTU and first day of trading in TO 1
Tue, May 07, 2024 16:00 CET Report this content
Diagonal Bio AB's ("Diagonal Bio" or the "Company") rights issue of units, with a subs... |
| 24.04.2024 | Diagonal Bio AB announces outcome of rights issue | Diagonal Bio AB announces outcome of rights issue
Wed, Apr 24, 2024 09:30 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEA... |
| 11.04.2024 | Brain+ announces registration of directed issue with the Danish Business Authority | Brain+ announces registration of directed issue with the Danish Business Authority
Thu, Apr 11, 2024 10:08 CET Report this content
Copenhagen, Denmark, April 10, 2024 – Brain+ A/S (Nasdaq First North: BRAINP)
New shares from the directed is... |
| 10.04.2024 | Brain+ announces registration of series TO 3 warrant exercise with the Danish Business Authority | Brain+ announces registration of series TO 3 warrant exercise with the Danish Business Authority
Wed, Apr 10, 2024 11:03 CET Report this content
COMPANY ANNOUNCEMENT
New shares from the exercise of Brain+ warrants of series TO 3 have been r... |
| 08.04.2024 | The subscription period in Diagonal Bio AB rights issue commences today | The subscription period in Diagonal Bio AB rights issue commences today
Mon, Apr 08, 2024 08:00 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, ... |
| 03.04.2024 | Diagonal Bio AB publishes a prospectus because of upcoming rights issue | Diagonal Bio AB publishes a prospectus because of upcoming rights issue
Wed, Apr 03, 2024 18:00 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, ... |
| 26.03.2024 | Brain+ announces the outcome of its series TO 3 warrant exercise and decision to carry out a directed share issue to cover guarantor commitments | Brain+ announces the outcome of its series TO 3 warrant exercise and decision to carry out a directed share issue to cover guarantor commitments
Tue, Mar 26, 2024 16:31 CET Report this content
Copenhagen, Denmark, March 26, 2024– Brain+ A/S... |
| 26.03.2024 | Brain+ A/S specifies how to get TO 3 warrant compensation | Brain+ A/S specifies how to get TO 3 warrant compensation
Tue, Mar 26, 2024 09:20 CET Report this content
Copenhagen, Denmark, March 26, 2024 – Brain+ A/S (Nasdaq First North: BRAINP)
As announced on March 7, 2024, compensation is offered t... |
| 20.03.2024 | Brain+ A/S announces last day of trading in its warrants of series TO 3 | Brain+ A/S announces last day of trading in its warrants of series TO 3
Wed, Mar 20, 2024 10:54 CET Report this content
COMPANY ANNOUNCEMENT
Copenhagen, Denmark, 20 March 2024 – Brain+ A/S (Nasdaq First North: BRAINP)
Today, 20 March 2024 i... |
| 15.03.2024 | Brain+ announces that 77% of its warrants of series TO 3 are now covered by commitments | Brain+ announces that 77% of its warrants of series TO 3 are now covered by commitments
Fri, Mar 15, 2024 11:07 CET Report this content
Copenhagen, Denmark, 15 March 2024 – Brain+ A/S (Nasdaq First North: BRAINP)
Firm commitments of exercis... |
| 11.03.2024 | Brain+ announces that 58% of its warrants of series TO 3 are covered by early commitments | Brain+ announces that 58% of its warrants of series TO 3 are covered by early commitments
Mon, Mar 11, 2024 12:54 CET Report this content
COMPANY ANNOUNCEMENT
Members of management and board members/observers have committed to exercise all ... |
| 07.03.2024 | Brain+ A/S announces amended terms for upcoming TO 3 warrant exercise | Brain+ A/S announces amended terms for upcoming TO 3 warrant exercise
Thu, Mar 07, 2024 08:52 CET Report this content
Brain+ A/S (Nasdaq First North: BRAINP) - This announcement constitutes inside information that Brain+ is obliged to make ... |
| 08.12.2023 | Genetic Analysis publishes information memorandum relating to the previously announced subsequent offering | Genetic Analysis publishes information memorandum relating to the previously announced subsequent offering
Fri, Dec 08, 2023 15:40 CET Report this content
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED S... |
| 08.12.2023 | Genetic Analysis announces final number of subscription rights received per existing share in the previously announced subsequent offering | Genetic Analysis announces final number of subscription rights received per existing share in the previously announced subsequent offering
Fri, Dec 08, 2023 13:35 CET Report this content
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTL... |
| 03.11.2023 | Subscriptions received in separate tranche of previously announced directed share issue | Subscriptions received in separate tranche of previously announced directed share issue
Fri, Nov 03, 2023 08:56 CET Report this content
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, THE UNITED K... |
| 24.10.2023 | Brain+ announces registration with the Danish Business Authority and first day of trading of new shares | Brain+ announces registration with the Danish Business Authority and first day of trading of new shares
Tue, Oct 24, 2023 14:40 CET Report this content
The Brain+ series TO 2 warrant exercise and directed share issue have been registered wi... |
| 18.10.2023 | Brain+ announces the outcome of its series TO 2 warrant exercise and decision to carry out a directed share issue to cover guarantor commitments | Brain+ announces the outcome of its series TO 2 warrant exercise and decision to carry out a directed share issue to cover guarantor commitments
Wed, Oct 18, 2023 09:53 CET Report this content
COMPANY ANNOUNCEMENT
Brain+ announces that 74.3... |
| 12.10.2023 | Brain+ announces additional commitments in the ongoing exercise of warrants of series TO 2 to reach now a coverage of almost 50% | Brain+ announces additional commitments in the ongoing exercise of warrants of series TO 2 to reach now a coverage of almost 50%
Thu, Oct 12, 2023 14:55 CET Report this content
Brain+ has received additional new commitments from existing sh... |
| 12.10.2023 | Brain+ A/S announces last day of trading in warrants of series TO 2 | Brain+ A/S announces last day of trading in warrants of series TO 2
Thu, Oct 12, 2023 08:30 CET Report this content
Copenhagen, Denmark, 12 October 2023 – Brain+ A/S (Nasdaq First North: BRAINP)
Today, 12 October is the last day of trading ... |
| 10.10.2023 | Brain+ announces commitments from its largest shareholders in the ongoing exercise of warrants of series TO 2 | Brain+ announces commitments from its largest shareholders in the ongoing exercise of warrants of series TO 2
Tue, Oct 10, 2023 08:30 CET Report this content
COMPANY ANNOUNCEMENT
Copenhagen, Denmark, 10 October 2023 – Brain+ A/S (Nasdaq Fir... |
| 29.09.2023 | Brain+ A/S announces the exercise price for its warrants of series TO 2 | Brain+ A/S announces the exercise price for its warrants of series TO 2
Fri, Sep 29, 2023 08:30 CET Report this content
COMPANY ANNOUNCEMENT
Copenhagen, Denmark, September 29, 2023 – Brain+ A/S (Nasdaq First North: BRAINP)
NOT FOR RELEASE, ... |
| 15.09.2023 | The Board of Directors of Calmark proposes for the extraordinary general meeting to decide on a rights issue in order to identify partners and accelerate sales activities | The Board of Directors of Calmark proposes for the extraordinary general meeting to decide on a rights issue in order to identify partners and accelerate sales activities
Fri, Sep 15, 2023 08:00 CET Report this content
The Board of Director... |
| 12.06.2023 | Brain+ A/S carries out a directed issue as compensation to guarantors of its unit rights issue | Brain+ A/S carries out a directed issue as compensation to guarantors of its unit rights issue
Mon, Jun 12, 2023 09:15 CET Report this content
COMPANY ANNOUNCEMENT
Copenhagen, Denmark, June 12, 2023 – Brain+ A/S (Nasdaq First North: BRAINP)... |
| 09.06.2023 | Brain+ A/S announces the first day of trading for the new shares and warrants from its rights issue | Brain+ A/S announces the first day of trading for the new shares and warrants from its rights issue
Fri, Jun 09, 2023 08:36 CET Report this content
COMPANY ANNOUNCEMENT
Copenhagen, Denmark, June 9, 2023 – Brain+ A/S (Nasdaq First North: BRA... |
| 06.06.2023 | Brain+ A/S announces a delay of the first day of trading for the new shares from its rights issue | Brain+ A/S announces a delay of the first day of trading for the new shares from its rights issue
Tue, Jun 06, 2023 16:29 CET Report this content
COMPANY ANNOUNCEMENT
Copenhagen, Denmark, June 6, 2023 – Brain+ A/S (Nasdaq First North: BRAIN... |
| 22.05.2023 | PHI AB’s warrant exercise registered with the Swedish Companies Registration Office | PHI AB’s warrant exercise registered with the Swedish Companies Registration Office
Mon, May 22, 2023 13:35 CET Report this content
Phase Holographic Imaging PHI AB (“PHI” or the “Company”) today announces that the new shares from the exerc... |
| 17.05.2023 | The subscription period in Carbiotix AB´s issue of units starts today | The subscription period in Carbiotix AB´s issue of units starts today
Wed, May 17, 2023 08:30 CET Report this content
Today, the 17th of May 2023, the subscription period in Carbiotix AB’s ("Carbiotix" or "Company") issu... |
| 10.05.2023 | The subscription period in Brain+ rights issue begins today | The subscription period in Brain+ rights issue begins today
Wed, May 10, 2023 08:30 CET Report this content
COMPANY ANNOUNCEMENT
Copenhagen, Denmark, May 10, 2023 – Brain+ A/S (Nasdaq First North: BRAINP)
NOT FOR RELEASE, DISTRIBUTION OR PU... |
| 04.05.2023 | TO 3 Warrants Subscribed to 100 % | TO 3 Warrants Subscribed to 100 %
Thu, May 04, 2023 12:58 CET Report this content
On 2 May 2023, the exercise period for warrants of series TO 3 (“TO 3”), which were issued in connection with Phase Holographic Imaging PHI AB’s (“PHI” or the... |
| 03.05.2023 | CHOSA Oncology AB announces approved re-listing memorandum | CHOSA Oncology AB announces approved re-listing memorandum
Wed, May 03, 2023 17:15 CET Report this content
CHOSA Oncology AB (publ) ("CHOSA" or the "Company"), formerly RhoVac, announces that Spotlight Stock Market (&quo... |
| 02.05.2023 | Brain+ A/S publishes supplement to prospectus | Brain+ A/S publishes supplement to prospectus
Tue, May 02, 2023 11:46 CET Report this content
COMPANY ANNOUNCEMENT
Copenhagen, Denmark, May 2, 2023 – Brain+ A/S (Nasdaq First North: BRAINP)
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRE... |
| 24.04.2023 | Last day of trading in warrants of series TO 3 is 27 April 2023 | Last day of trading in warrants of series TO 3 is 27 April 2023
Mon, Apr 24, 2023 11:10 CET Report this content
Thursday, 27 April 2023, is the last day of trading in warrants of series TO 3, which were issued in connection with Phase Holog... |
| 24.04.2023 | Approval and publication of prospectus | Approval and publication of prospectus
Mon, Apr 24, 2023 09:40 CET Report this content
COMPANY ANNOUNCEMENT
Copenhagen, Denmark, April 24, 2023 – Brain+ A/S (Nasdaq First North: BRAINP)
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY... |
| 24.04.2023 | The Board of Directors in Brain+ A/S has resolved on the previously announced intention to execute a rights issue of units | The Board of Directors in Brain+ A/S has resolved on the previously announced intention to execute a rights issue of units
Mon, Apr 24, 2023 08:39 CET Report this content
COMPANY ANNOUNCEMENT
Copenhagen, Denmark, April 24, 2023 – Brain+ A/S... |
| 21.04.2023 | PHI enters into underwriting commitment with Altium in ongoing exercise of TO 3 warrants | PHI enters into underwriting commitment with Altium in ongoing exercise of TO 3 warrants
Fri, Apr 21, 2023 08:04 CET Report this content
Phase Holographic Imaging PHI AB ("PHI" or the "Company") hereby announces that the... |
| 13.04.2023 | Stayble Therapeutics AB announces outcome from concluded rights issue | Stayble Therapeutics AB announces outcome from concluded rights issue
Thu, Apr 13, 2023 20:07 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANA... |
| 11.04.2023 | The exercise period for warrants of series TO 3 begins today | The exercise period for warrants of series TO 3 begins today
Tue, Apr 11, 2023 14:27 CET Report this content
Today is the first day of the exercise period for Phase Holographic Imaging PHI AB’s (“PHI” or the “Company”) warrants of series TO... |
| 05.04.2023 | The subscription price for warrants of series TO 3 has been set at SEK 3.78 per share | The subscription price for warrants of series TO 3 has been set at SEK 3.78 per share
Wed, Apr 05, 2023 13:50 CET Report this content
Phase Holographic Imaging PHI AB (“PHI” or the “Company”) hereby announces the subscription price for the ... |
| 29.03.2023 | Stayble Therapeutics AB publishes supplementary prospectus regarding the rights issue | Stayble Therapeutics AB publishes supplementary prospectus regarding the rights issue
Wed, Mar 29, 2023 13:25 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRA... |
| 29.03.2023 | The Board of Directors in Brain+ A/S intends to execute a rights issue of units of approximately DKK 15.7 million in order to intensify commercial activities | The Board of Directors in Brain+ A/S intends to execute a rights issue of units of approximately DKK 15.7 million in order to intensify commercial activities
Wed, Mar 29, 2023 08:56 CET Report this content
COMPANY ANNOUNCEMENT
Copenhagen, D... |
| 28.03.2023 | StaybIe Therapeutics AB receives additional underwriting commitments for the ongoing rights issue | StaybIe Therapeutics AB receives additional underwriting commitments for the ongoing rights issue
Tue, Mar 28, 2023 17:40 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED ST... |
| 24.03.2023 | Today the subscription period of StaybIe Therapeutics AB’s rights issue starts | Today the subscription period of StaybIe Therapeutics AB’s rights issue starts
Fri, Mar 24, 2023 09:30 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JA... |
| 23.03.2023 | StaybIe Therapeutics AB receives additional pre-subscription and underwriting commitments for the upcoming rights issue | StaybIe Therapeutics AB receives additional pre-subscription and underwriting commitments for the upcoming rights issue
Thu, Mar 23, 2023 21:30 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN... |
| 21.03.2023 | Polymer Factory announces last day of trading in BTA | Polymer Factory announces last day of trading in BTA
Tue, Mar 21, 2023 14:22 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, JAPAN, OR CANADA... |
| 17.03.2023 | Stayble Therapeutics AB publishes prospectus relating to the rights issue | Stayble Therapeutics AB publishes prospectus relating to the rights issue
Fri, Mar 17, 2023 13:40 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, ... |
| 13.03.2023 | Polymer Factory announces outcome of the rights issue | Polymer Factory announces outcome of the rights issue
Mon, Mar 13, 2023 16:02 CET Report this content
NOT FOR PUBLICATION, DISCLOSURE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, CANADA, JAPAN, SOUTH KOREA, AUSTRALIA... |
| 10.03.2023 | Clinical Laserthermia Systems AB announces that the date for conversion of interim shares is estimated to 15 March 2023 | Clinical Laserthermia Systems AB announces that the date for conversion of interim shares is estimated to 15 March 2023
Fri, Mar 10, 2023 17:00 CET Report this content
Lund, Sweden March 10, 2023 – Clinical Laserthermia Systems AB (“CLS” or... |
| 02.03.2023 | Clinical Laserthermia Systems AB receives approx. SEK 12.8 million through warrant exercise | Clinical Laserthermia Systems AB receives approx. SEK 12.8 million through warrant exercise
Thu, Mar 02, 2023 08:30 CET Report this content
Lund, Sweden – On 28 February 2023, the exercise period for warrants of series TO 5 B, which were is... |
| 24.02.2023 | Last day of trading in warrants of series TO 5 B is today 24 February 2023 | Last day of trading in warrants of series TO 5 B is today 24 February 2023
Fri, Feb 24, 2023 08:30 CET Report this content
Lund, Sweden – Today, 24 February 2023, is the last day of trading in warrants of series TO 5 B, which were issued in... |
| 24.02.2023 | The subscription period in Polymer Factory’s rights issue begins today | The subscription period in Polymer Factory’s rights issue begins today
Fri, Feb 24, 2023 08:00 CET Report this content
Today, 24 February 2023, is the first day of the subscription period in Polymer Factory Sweden AB’s (“Polymer Factory” or... |
| 23.02.2023 | Clinical Laserthermia Systems AB enters underwriting commitments in the ongoing exercise of warrants of series TO 5 B corresponding to approximately SEK 2.6 million | Clinical Laserthermia Systems AB enters underwriting commitments in the ongoing exercise of warrants of series TO 5 B corresponding to approximately SEK 2.6 million
Thu, Feb 23, 2023 17:10 CET Report this content
Lund, Sweden – Clinical Las... |
| 23.02.2023 | Polymer Factory publishes memorandum relating to the rights issue | Polymer Factory publishes memorandum relating to the rights issue
Thu, Feb 23, 2023 08:24 CET Report this content
NOT FOR PUBLICATION, DISCLOSURE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, CANADA, JAPAN, SOUTH KORE... |
| 22.02.2023 | Stayble Therapeutics AB starts development of a new clinical indication and decides on a rights issue of approximately MSEK 35.2 | Stayble Therapeutics AB starts development of a new clinical indication and decides on a rights issue of approximately MSEK 35.2
Wed, Feb 22, 2023 21:14 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIR... |
| 22.02.2023 | Polymer Factory signs subscription commitments with all board members, CEO, and external investors in conjunction to planned rights issue | Polymer Factory signs subscription commitments with all board members, CEO, and external investors in conjunction to planned rights issue
Wed, Feb 22, 2023 08:59 CET Report this content
NOT FOR PUBLICATION, DISCLOSURE OR DISTRIBUTION, DIREC... |
| 27.01.2023 | The Board of Polymer Factory Sweden AB (publ) resolves on a rights issue of shares of approx. SEK 8.8 million | The Board of Polymer Factory Sweden AB (publ) resolves on a rights issue of shares of approx. SEK 8.8 million
Fri, Jan 27, 2023 08:44 CET Report this content
NOT FOR PUBLICATION, DISCLOSURE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ... |
| 23.12.2022 | Last day of trading in BTU and first day of trading in warrants of series TO 1 in Audientes A/S | Last day of trading in BTU and first day of trading in warrants of series TO 1 in Audientes A/S
Fri, Dec 23, 2022 12:05 CET Report this content
Company announcement no. 34-2022
December 23, 2022
Audientes A/S (CVR. No. 36 04 76 31) hereby a... |
| 21.12.2022 | Audientes A/S carries out a directed issue to compensate guarantors | Audientes A/S carries out a directed issue to compensate guarantors
Wed, Dec 21, 2022 23:15 CET Report this content
Company announcement no. 33-2022
December 21, 2022
Audientes A/S (CVR. No. 36 04 76 31) has completed its fully subscribed p... |
| 20.12.2022 | Audientes A/S Rights Issue of Units fully subscribed | Audientes A/S Rights Issue of Units fully subscribed
Tue, Dec 20, 2022 13:05 CET Report this content
Company announcement no. 32-2022
December 20, 2022
Audientes A/S (CVR. No. 36 04 76 31) announces the outcome of its pre-emptive rights iss... |
| 01.12.2022 | The subscription period in Audientes A/S’s rights issue of units begins today | The subscription period in Audientes A/S’s rights issue of units begins today
Thu, Dec 01, 2022 09:25 CET Report this content
Company announcement no. 31-2022
December 1, 2022
Today, 1 December 2022, is the first day of the subscription per... |
| 23.11.2022 | Audientes A/S publishes prospectus relating to the rights issue | Audientes A/S publishes prospectus relating to the rights issue
Wed, Nov 23, 2022 19:18 CET Report this content
Company announcement no. 30-2022
November 23, 2022
Today, Audientes A/S (CVR No. 36047631) publishes the prospectus relating to ... |
| 18.11.2022 | The Board of Audientes A/S resolves on a rights issue of units of approx. DKK 24.3 million in total, extends a previous loan, and communicates new objectives | The Board of Audientes A/S resolves on a rights issue of units of approx. DKK 24.3 million in total, extends a previous loan, and communicates new objectives
Fri, Nov 18, 2022 20:50 CET Report this content
Company announcement no. 28-2022
N... |
| 09.09.2022 | Clinical Laserthermia Systems AB (publ) publishes the outcome of the rights issue of units | Clinical Laserthermia Systems AB (publ) publishes the outcome of the rights issue of units
Fri, Sep 09, 2022 19:00 CET Report this content
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES O... |
| 07.09.2022 | CS MEDICA A/S warrant exercise registered with the Danish Companies Registration Office | CS MEDICA A/S warrant exercise registered with the Danish Companies Registration Office
Wed, Sep 07, 2022 19:02 CET Report this content
On Thursday, 1 September 2022, the exercise period for CS MEDICA A/S (“CS MEDICA” or the “Company”) warr... |
| 06.09.2022 | CS MEDICA A/S raises approx. DKK 9.9 million through warrant exercise | CS MEDICA A/S raises approx. DKK 9.9 million through warrant exercise
Tue, Sep 06, 2022 08:45 CET Report this content
During the period 18 August 2022 – 1 September 2022, holders of warrants of series TO 1 have been entitled to subscribe fo... |
